Titan Pharmaceuticals Inc (TTNP): James R Mcnab , director of Titan Pharmaceuticals Inc purchased 20,000 shares on May 31, 2016. The Insider buying transaction was reported by the company on May 31, 2016 to the Securities and Exchange Commission. The shares were purchased at $7.03 per share for a total value of $140,600.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Feb 22, 2016, Sunil Bhonsle (CEO) purchased 11,763 shares at $3.56 per share price.On Jan 14, 2016, James R Mcnab (director) purchased 16,363 shares at $3.16 per share price.Also, On Jan 11, 2016, Marc Rubin (Executive Chairman) purchased 5,000 shares at $3.25 per share price.
Titan Pharmaceuticals Inc. (Titan) is a specialty pharmaceutical company developing therapeutics for the treatment of medical disorders. The Company’s product development programs utilize its long-term drug delivery platform ProNeura. The Company’s drug candidate Probuphine is being developed for the long term maintenance treatment of opioid dependence. Titan’s ProNeura continuous drug delivery system consists of a small solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. Titan’s drug candidate Probuphine is in Phase III clinical study stage. The Company is also engaged in the development of its ProNeura-Ropinirole product to deliver dopamine agonists for the treatment of Parkinson’s disease. The Company has licensed the rights to commercialize Probuphine in the United States and Canada to Braeburn Pharmaceuticals Sprl (Braeburn).